{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:05:16Z","timestamp":1781251516407,"version":"3.54.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tenofovir-sparing antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) are increasingly used. However, these regimens may increase the risk of new hepatitis B virus (HBV) infection or reactivation due to lack of full activity against HBV. The magnitude and mechanism of risk can vary by baseline HBV serologic profile and need to be discussed with the patient before switching regimens. Importantly, these risks can be mitigated through HBV screening, vaccination, and post-switch monitoring. Here, we synthesize the evidence across different clinical scenarios and propose a practical workflow to reduce the potential but preventable risk during transitions to tenofovir-sparing regimens. Finally, we highlight knowledge gaps and outline future research priorities. The decision to switch to tenofovir-sparing ART or PrEP should not be made solely through the lens of HIV efficacy and convenience and must incorporate HBV prevention and reactivation risk.<\/jats:p>","DOI":"10.1093\/cid\/ciag322","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:16:25Z","timestamp":1779794185000},"source":"Crossref","is-referenced-by-count":0,"title":["Don't Drop the B: Risk of Hepatitis B Virus Infection and Reactivation in the Era of Tenofovir-Sparing Regimens for Treatment and Prevention of Human Immunodeficiency Virus"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2478-3447","authenticated-orcid":false,"given":"Tzu-Hao","family":"Lee","sequence":"first","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine , Houston, Texas ,","place":["USA"]},{"name":"Division of Abdominal Transplant, Department of Surgery, Baylor College of Medicine , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2136-7763","authenticated-orcid":false,"given":"Debika","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA , Los Angeles, California ,","place":["USA"]},{"name":"Greater Los Angeles VA Healthcare System , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-9666","authenticated-orcid":false,"given":"H Nina","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Allergy & Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington ,","place":["USA"]},{"name":"Madison Clinic and Liver Clinic, Harborview Medical Center , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"2026061203515462900_ciag322-B1","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3018(22)00123-0","article-title":"Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B","volume":"9","author":"Mohareb","year":"2022","journal-title":"Lancet HIV"},{"key":"2026061203515462900_ciag322-B2"},{"key":"2026061203515462900_ciag322-B3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/jiw195","article-title":"Dually active HIV\/HBV antiretrovirals as protection against incident hepatitis B infections: potential for prophylaxis","volume":"214","author":"Shilaih","year":"2016","journal-title":"J Infect Dis"},{"key":"2026061203515462900_ciag322-B4","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1097\/HEP.0000000000000384","article-title":"Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men","volume":"77","author":"Mizushima","year":"2023","journal-title":"Hepatology"},{"key":"2026061203515462900_ciag322-B5","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2026061203515462900_ciag322-B6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061203515462900_ciag322-B7","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","article-title":"Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks","volume":"24","author":"Murray","year":"2020","journal-title":"AIDS Behav"},{"key":"2026061203515462900_ciag322-B8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/cid\/ciae531","article-title":"High retention and adherence with rapid long-acting injectable preexposure prophylaxis implementation in an urban safety net clinic population","volume":"80","author":"Spinelli","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026061203515462900_ciag322-B9","author":"Haser G"},{"key":"2026061203515462900_ciag322-B10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/M15-0547","article-title":"Incident hepatitis B virus infection in HIV-infected and HIV-uninfected men who have sex with men from pre-HAART to HAART periods: a cohort study","volume":"163","author":"Falade-Nwulia","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026061203515462900_ciag322-B11","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/hep.31991","article-title":"Prevalence of HBV infection, vaccine-induced immunity, and susceptibility among at-risk populations: US households, 2013\u20132018","volume":"74","author":"Roberts","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"key":"2026061203515462900_ciag322-B12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/QAI.0000000000003239","article-title":"Brief report: hepatitis B infection or reactivation after switch to 2-drug antiretroviral therapy: a case series, literature review, and management discussion","volume":"94","author":"Vasishta","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026061203515462900_ciag322-B13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/QAD.0b013e328334bddb","article-title":"Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption","volume":"24","author":"Dore","year":"2010","journal-title":"AIDS (London, England)"},{"key":"2026061203515462900_ciag322-B14","doi-asserted-by":"crossref","first-page":"ciaf634.","DOI":"10.1093\/cid\/ciaf634","article-title":"Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: a case series and lessons for practice","author":"Olcott","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026061203515462900_ciag322-B15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1086\/649885","article-title":"Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years","volume":"50","author":"Chun","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026061203515462900_ciag322-B16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7326\/M17-1689","article-title":"Low prevalence of hepatitis B vaccination among patients receiving medical care for HIV infection in the United States, 2009 to 2012","volume":"168","author":"Weiser","year":"2018","journal-title":"Ann Intern Med"},{"key":"2026061203515462900_ciag322-B17","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1473-3099(12)70243-8","article-title":"Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1","volume":"12","author":"Whitaker","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"2026061203515462900_ciag322-B18","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jama.2025.9894","article-title":"HepB-CpG vaccine in people with HIV and prior nonresponse to HBV vaccine: the BEe-HIVe trial end-of-study results","volume":"334","author":"Marks","year":"2025","journal-title":"JAMA"},{"key":"2026061203515462900_ciag322-B19","doi-asserted-by":"crossref","first-page":"ofad500.057","DOI":"10.1093\/ofid\/ofad500.057","article-title":"1026. hepatitis B reactivation in persons with HIV with positive hepatitis B core antibody after switching to antiretroviral therapy without hepatitis B activity","volume":"10","author":"Denyer","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026061203515462900_ciag322-B20","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/QAI.0000000000000941","article-title":"Isolated hepatitis B core antibody is associated with advanced hepatic fibrosis in HIV\/HCV infection but not in HIV infection alone","volume":"72","author":"Bhattacharya","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026061203515462900_ciag322-B21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00126334-200407010-00015","article-title":"Occult hepatitis B in HIV-infected patients","volume":"36","author":"Shire","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026061203515462900_ciag322-B22"},{"key":"2026061203515462900_ciag322-B23","doi-asserted-by":"crossref","first-page":"ofy251","DOI":"10.1093\/ofid\/ofy251","article-title":"Hepatitis B virus (HBV) infection and Re-activation during nucleos(t)ide reverse transcriptase inhibitor-sparing antiretroviral therapy in a high-HBV endemicity setting","volume":"5","author":"Abdullahi","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026061203515462900_ciag322-B24","doi-asserted-by":"crossref","first-page":"ofaf266","DOI":"10.1093\/ofid\/ofaf266","article-title":"To switch or not to switch to long-acting injectable cabotegravir\/rilpivirine in PWH with past hepatitis B virus (HBV) coinfection: which HBV markers to manage risk of HBV reactivation?","volume":"12","author":"Ollier","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026061203515462900_ciag322-B25","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/infdis\/jiw011","article-title":"Vaccination against hepatitis B virus (HBV) in HIV-1-infected patients with isolated anti-HBV core antibody: the ANRS HB EP03 CISOVAC prospective study","volume":"213","author":"Piroth","year":"2016","journal-title":"J Infect Dis"},{"key":"2026061203515462900_ciag322-B26","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"2026061203515462900_ciag322-B27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"2026061203515462900_ciag322-B28","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.31839","article-title":"Risk of HCC with hepatitis B viremia among HIV\/HBV-coinfected persons in North America","volume":"74","author":"Kim","year":"2021","journal-title":"Hepatology (Baltimore, MD)"},{"key":"2026061203515462900_ciag322-B29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.15585\/mmwr.mm6715a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026061203515462900_ciag322-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"2026061203515462900_ciag322-B31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/QAI.0000000000000857","article-title":"The safety of tenofovir-emtricitabine for HIV pre-exposure prophylaxis (PrEP) in individuals with active hepatitis B","volume":"71","author":"Solomon","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026061203515462900_ciag322-B32"},{"key":"2026061203515462900_ciag322-B33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"2026061203515462900_ciag322-B34","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","article-title":"AASLD\/IDSA practice guideline on treatment of chronic hepatitis B","volume":"83","author":"Ghany","year":"2026","journal-title":"Hepatology (Baltimore, MD)"},{"key":"2026061203515462900_ciag322-B35","doi-asserted-by":"crossref","first-page":"100720","DOI":"10.1016\/j.jhepr.2023.100720","article-title":"Utility of novel viral and immune markers in predicting HBV treatment endpoints: a systematic review of treatment discontinuation studies","volume":"5","author":"Zeng","year":"2023","journal-title":"JHEP Rep"},{"key":"2026061203515462900_ciag322-B36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2018.05.047","article-title":"Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy","volume":"17","author":"Chi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061203515462900_ciag322-B37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/hepr.13470","article-title":"Discordance of hepatitis B vaccination policies for healthcare workers between the USA, the UK, and Germany","volume":"50","author":"Komatsu","year":"2020","journal-title":"Hepatol Res"},{"key":"2026061203515462900_ciag322-B38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.2024.24490","article-title":"HepB-CpG vs HepB-alum vaccine in people with HIV and prior vaccine nonresponse: the BEe-HIVe randomized clinical trial","volume":"333","author":"Marks","year":"2025","journal-title":"JAMA"},{"key":"2026061203515462900_ciag322-B39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/infdis\/jix595","article-title":"Laboratory testing of a cohort of commercially insured users of HIV preexposure prophylaxis in the United States, 2011\u20132015","volume":"217","author":"Huang","year":"2018","journal-title":"J Infect Dis"},{"key":"2026061203515462900_ciag322-B40","doi-asserted-by":"crossref","first-page":"ofaf638","DOI":"10.1093\/ofid\/ofaf638","article-title":"A quality improvement pilot to increase hepatitis B screening and optimize patient selection for the switch to two-drug antiretroviral regimens in people with HIV","volume":"12","author":"Margolis","year":"2025","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag322\/68409489\/ciag322.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag322\/68409489\/ciag322.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:52:02Z","timestamp":1781250722000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciag322\/8695898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag322","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"article-number":"ciag322"}}